Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma (clinicaltrials.gov) - Oct 7, 2026 - P2 | N=80 | Recruiting | Sponsor: M.D. Anderson Cancer Center | Active, not recruiting ➔ Recruiting | N=60 ➔ 80
Enrollment change • Enrollment open • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology • CD20
|